Callahan MK, et al. - In a phase I dose-escalation study, concurrent therapy with nivolumab (NIVO) and ipilimumab (IPI) showed clinical activity in patients with previously treated or untreated advanced melanoma. Herein, long-term follow-up data from study CA209-004 demonstrated a 3-year overall survival rate of 63% in patients with advanced melanoma treated with NIVO plus IPI combination therapy; this represented the highest observed rate for this patient population. Additional evidence for the durable clinical activity of immune checkpoint inhibitors in the treatment of advanced melanoma was demonstrated.